Evidence map›Paper›PMID 35982660›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Viral and Symptom Rebound in Untreated COVID-19 Infection.

Rinki Deo, Manish C Choudhary, Carlee Moser, Justin Ritz, Eric S Daar, David A Wohl, Alexander L Greninger, Joseph J Eron, Judith S Currier, Michael D Hughes and 4 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 21 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Rinki DeoBrigham and Women's Hospital, Harvard Medical School, Boston, MA.
Manish C ChoudharyBrigham and Women's Hospital, Harvard Medical School, Boston, MA.
Carlee MoserHarvard T.H. Chan School of Public Health, Boston, MA.
Justin RitzHarvard T.H. Chan School of Public Health, Boston, MA.
Eric S DaarLundquist Institute at Harbor-University of California, Los Angeles Medical Center, Torrance, CA.
David A WohlUniversity of North Carolina, Chapel Hill, NC.
Alexander L GreningerUniversity of Washington Medical Center, Seattle, WA.
Joseph J EronUniversity of North Carolina, Chapel Hill, NC.
Judith S CurrierDavid Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
Michael D HughesHarvard T.H. Chan School of Public Health, Boston, MA.
Davey M SmithUniversity of California, San Diego, San Diego, CA.
Kara W ChewDavid Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA.
ACTIV-2/A5401 Study Team
Brigham and Women's Hospital · USHarvard University · USUniversity of California, Los Angeles · USUniversity of North Carolina at Chapel Hill · USUCLA Medical Center · USUniversity of California San Diego · USUniversity of Washington Medical Center · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

Background: There are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpatients with mild-moderate COVID-19. Methods: The study population included 568 participants enrolled in the ACTIV-2/A5401 platform trial who received placebo. Anterior nasal swabs were collected for SARS-CoV-2 RNA testing on days 0-14, 21 and 28. Participants recorded the severity of 13 targeted symptoms daily from day 0 to 28. Viral rebound was defined as ≥0.5 log Findings: In both the primary and secondary analyses, 12% of participants had viral rebound. Viral rebounders were older than non-rebounders (median 54 vs 47 years, P=0.04). Symptom rebound occurred in 27% of participants after initial symptom improvement and in 10% of participants after initial symptom resolution. The combination of high-level viral rebound to ≥5.0 log Interpretation: Viral RNA rebound or symptom relapse in the absence of antiviral treatment is common, but the combination of high-level viral and symptom rebound is rare.

Indexed as

COVID-19Paxlovidsymptom reboundviral rebound

Identifiers

PMID35982660
PMCPMC9387151
OpenAlexW4289519210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.